OncoCyte Corporation to Present at Cowen and Company 37th Annual Health Care Conference

Print
| Source: OncoCyte Corporation

ALAMEDA, Calif., March 01, 2017 (GLOBE NEWSWIRE) -- OncoCyte Corporation (NYSE MKT:OCX), a developer of novel, non-invasive blood based tests for the early detection of cancer, announced today that William Annett, Chief Executive Officer, is scheduled to present an overview of the company and its progress at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. The presentation will begin at 9:20 a.m. ET on Wednesday, March 8th, 2017 at the Boston Marriott Copley Place.

Please note the attendance at the conference is by invitation only.  Investors interested in scheduling a one-on-one meeting with OncoCyte’s management during the conference should contact their Cowen representative.

A live audio and/or webcast and subsequent archived replay of OncoCyte’s presentations may be accessed via the Investors section of the Company’s website under “Events & Presentations” at http://investors.oncocyte.com/. The replay will be available for 90 days after the event.

About OncoCyte Corporation

OncoCyte is focused on the development and commercialization of novel, non-invasive blood and urine (“liquid biopsy”) diagnostic tests for the early detection of cancer to improve health outcomes through earlier diagnoses, to reduce the cost of care through the avoidance of more costly diagnostic procedures, including invasive biopsy and cystoscopic procedures, and to improve the quality of life for cancer patients.

While current biopsy tests use invasive surgical procedures to provide tissue samples in order to determine if a tumor is benign or malignant, OncoCyte is developing a next generation of diagnostic tests that will be based on liquid biopsies using blood or urine samples. OncoCyte’s pipeline products are intended to be confirmatory diagnostics for lung, bladder and breast cancer. OncoCyte’s diagnostic tests are being developed using proprietary sets of genetic and protein biomarkers that are differentially expressed in specific types of cancer. For more information visit www.oncocyte.com.

Investor Contact:

EVC Group, Inc.
Michael Polyviou/Doug Sherk
212-850-6020/646-445-4800
mpolyviou@evcgroup.com / dsherk@evcgroup.com